Medical School

  • Brown University , 2007 , Providence , RI


  • Boston Combined Residency Program (BCRP) , 2010 , Boston , MA


Pediatric Hematology-Oncology
  • Boston Children's Hospital/Dana-Farber Cancer Institute , 2014 , Boston , MA


Dr. Stacy Croteau is a pediatric hematologist and clinical researcher at Dana-Farber/Boston Children’s Cancer and Blood Disorders Center, where she specializes in bleeding and clotting disorders. She completed her undergraduate and medical education at Brown University and then pursued training in Pediatrics and Pediatric Hematology/Oncology at Boston Children's Hospital and Dana-Farber Cancer Institute. Dr. Croteau joined the Boston Hemophilia Center as the associate director in 2014 and became the medical director in 2019. She enjoys clinical care of pediatric patients and leading research efforts to push the frontier of the quality and innovation in our current standards of medical practice.

Dr. Croteau currently serves at the primary investigator for several industry-sponsored and investigator initiated clinical trials and as the national chair of the American Thrombosis Hemostasis Network (ATHN)/National Hemophilia Program Coordinating Center (NHPCC) Transition Working Group. She also serves on the American Society of Hematology's Scientific Committee for Hemostasis. Her primary areas of academic interest are early drug development, advancing an approach for rationally designed personalized-prophylaxis regimens in hemophilia, and quality improvement efforts targeting patient transition from pediatric to adult care.


  • American Board of Pediatrics, General Pediatrics
  • American Board of Pediatrics, Pediatric Hematology and Oncology


Publications powered by Harvard Catalyst Profiles

  1. Croteau SE, Frelinger AL, Gerrits AJ, Michelson AD. Decreased Platelet Surface Phosphatidylserine Predicts Increased Bleeding in Patients with Severe Factor VIII Deficiency. J Thromb Haemost. 2020 Dec 28. View abstract
  2. Shapiro AD, Ragni MV, Borhany M, Abajas YL, Tarantino MD, Holstein K, Croteau SE, Liesner R, Tarango C, Carvalho M, McGuinn C, Funding E, Kempton CL, Bidlingmaier C, Cohen A, Oldenburg J, Kearney S, Knoll C, Kuriakose P, Acharya S, Reiss UM, Kulkarni R, Witkop M, Lethagen S, Donfield S, LeBeau P, Berntorp E, Astermark J. Natural history study of factor IX deficiency with focus on treatment and complications (B-Natural). Haemophilia. 2020 Dec 05. View abstract
  3. Sidonio RF, Pipe SW, Callaghan MU, Valentino LA, Monahan PE, Croteau SE. Discussing investigational AAV gene therapy with hemophilia patients: A guide. Blood Rev. 2020 Nov 09; 100759. View abstract
  4. Croteau SE, Wang M, Wheeler AP. 2021 clinical trials update: Innovations in hemophilia therapy. Am J Hematol. 2021 Jan; 96(1):128-144. View abstract
  5. Jaffray J, Branchford B, Goldenberg N, Malvar J, Croteau SE, Silvey M, Fargo JH, Cooper JD, Bakeer N, Sposto R, Ji L, Zakai NA, Faustino EVS, Stillings A, Krava E, Young G, Mahajerin A. Development of a Risk Model for Pediatric Hospital-Acquired Thrombosis: A Report from the Children's Hospital-Acquired Thrombosis Consortium. J Pediatr. 2021 Jan; 228:252-259.e1. View abstract
  6. Al-Samkari H, Croteau SE. Beliefs, opinions and impact of emicizumab in haemophilia A patients: A National US Survey Study. Haemophilia. 2020 Sep 08. View abstract
  7. Malec LM, Cheng D, Witmer CM, Jaffray J, Kouides PA, Haley KM, Sidonio RF, Johnson K, Recht M, White G, Croteau SE, Ragni MV. The impact of extended half-life factor concentrates on prophylaxis for severe hemophilia in the United States. Am J Hematol. 2020 08; 95(8):960-965. View abstract
  8. Shui M, D'Angelo L, Croteau SE. Low von Willebrand factor in pediatric patients: Retrospective analysis of 293 cases informs diagnostic and therapeutic decision making. Pediatr Blood Cancer. 2020 09; 67(9):e28497. View abstract
  9. Al-Samkari H, Ozonoff A, Landschaft A, Kimia R, Harper MB, Croteau SE, Kimia AA. Utility of Blood Cultures and Empiric Antibiotics in Febrile Pediatric Hemophilia Patients With Central Venous Access Devices. Pediatr Emerg Care. 2020 Apr 28. View abstract
  10. Malec LM, Croteau SE, Callaghan MU, Sidonio RF. Spontaneous bleeding and poor bleeding response with extended half-life factor IX products: A survey of select US haemophilia treatment centres. Haemophilia. 2020 May; 26(3):e128-e129. View abstract
  11. Brucker WJ, Croteau SE, Prensner JR, Cullion K, Heeney MM, Lo J, McAlvin JB, Peeler K, Shah N, Yee CSK, Berry GT, Bodamer O. An emerging role for endothelial barrier support therapy for congenital disorders of glycosylation. J Inherit Metab Dis. 2020 07; 43(4):880-890. View abstract
  12. Croteau SE, Wheeler AP, Khan O, Haley KM, Borst AJ, Lattimore S, Yeung CHT, Iorio A. Pharmacokinetic-tailored approach to hemophilia prophylaxis: Medical decision making and outcomes. Res Pract Thromb Haemost. 2020 Feb; 4(2):326-333. View abstract
  13. Chelle P, Yeung CHT, Croteau SE, Lissick J, Balasa V, Ashburner C, Park YS, Bonanad S, Megías-Vericat JE, Nagao A, Wynn T, Corrales-Medina F, Tran H, Sharathkumar A, Chitlur M, Sarmiento S, Edginton A, Iorio A. Development and Validation of a Population-Pharmacokinetic Model for Rurioctacog Alfa Pegol (Adynovate®): A Report on Behalf of the WAPPS-Hemo Investigators Ad Hoc Subgroup. Clin Pharmacokinet. 2020 02; 59(2):245-256. View abstract
  14. Croteau SE, Cutter S, Hernandez G, Wicklund B, Dreyer Gillette ML, Haugstad K, Cooper DL, Ostrow V, Nadglowski J. Awareness, Care and Treatment In Obesity maNagement to inform Haemophilia Obesity Patient Empowerment (ACTION-TO-HOPE): Results of a survey of US patients with haemophilia and obesity (PwHO) and their partners and caregivers. Haemophilia. 2020 Jan; 26 Suppl 1:3-19. View abstract
  15. Neumeyer J, Lin RZ, Wang K, Hong X, Hua T, Croteau SE, Neufeld EJ, Melero-Martin JM. Bioengineering hemophilia A-specific microvascular grafts for delivery of full-length factor VIII into the bloodstream. Blood Adv. 2019 12 23; 3(24):4166-4176. View abstract
  16. McEneny-King A, Yeung CH, Edginton AN, Iorio A, Croteau SE. Clinical application of Web Accessible Population Pharmacokinetic Service-Hemophilia (WAPPS-Hemo): Patterns of blood sampling and patient characteristics among clinician users. Haemophilia. 2020 Jan; 26(1):56-63. View abstract
  17. Buranahirun C, Walsh KS, Mrakotsky C, Croteau SE, Rajpurkar M, Kearney S, Hannemann C, Wilkening GN, Shapiro KA, Cooper DL. Neuropsychological function in children with hemophilia: A review of the Hemophilia Growth and Development Study and introduction of the current eTHINK study. Pediatr Blood Cancer. 2020 01; 67(1):e28004. View abstract
  18. Rajpurkar M, Croteau SE, Boggio L, Cooper DL. Thrombotic events with recombinant activated factor VII (rFVIIa) in approved indications are rare and associated with older age, cardiovascular disease, and concomitant use of activated prothrombin complex concentrates (aPCC). J Blood Med. 2019; 10:335-340. View abstract
  19. Croteau SE, Cheng D, Cohen AJ, Holmes CE, Malec LM, Silvey M, Thornburg CD, Wheeler AP, Kouides PA, Raffini LJ, Neufeld EJ. Regional variation and cost implications of prescribed extended half-life factor concentrates among U.S. Haemophilia Treatment Centres for patients with moderate and severe haemophilia. Haemophilia. 2019 Jul; 25(4):668-675. View abstract
  20. Saini S, Croteau SE, Horling FM, Dunn AL. Factor IX inhibitors: Clinical and laboratory profiles of two patients with severe haemophilia B. Haemophilia. 2019 03; 25(2):e126-e129. View abstract
  21. Al-Samkari H, Croteau SE. Shifting Landscape of Hemophilia Therapy: Implications for Current Clinical Laboratory Coagulation Assays. Am J Hematol. 2018 Jun 08. View abstract
  22. Ragni MV, Croteau SE, Morfini M, Cnossen MH, Iorio A. Pharmacokinetics and the transition to extended half-life factor concentrates: communication from the SSC of the ISTH. J Thromb Haemost. 2018 07; 16(7):1437-1441. View abstract
  23. Croteau SE. Evolving Complexity in Hemophilia Management. Pediatr Clin North Am. 2018 06; 65(3):407-425. View abstract
  24. Croteau SE, Callaghan MU, Davis J, Dunn AL, Guerrera M, Khan O, Neufeld EJ, Raffini LJ, Recht M, Wang M, Iorio A. Focusing in on use of pharmacokinetic profiles in routine hemophilia care. Res Pract Thromb Haemost. 2018 Jul; 2(3):607-614. View abstract
  25. Iorio A, Edginton AN, Blanchette V, Blatny J, Boban A, Cnossen M, Collins P, Croteau SE, Fischer K, Hart DP, Ito S, Korth-Bradley J, Lethagen S, Lillicrap D, Makris M, Mathôt R, Morfini M, Neufeld EJ, Spears J. Performing and interpreting individual pharmacokinetic profiles in patients with Hemophilia A or B: Rationale and general considerations. Res Pract Thromb Haemost. 2018 Jul; 2(3):535-548. View abstract
  26. Berntorp E, Ågren A, Aledort L, Blombäck M, Cnossen MH, Croteau SE, von Depka M, Federici AB, Goodeve A, Goudemand J, Mannucci PM, Mourik M, Önundarson PT, Rodeghiero F, Szántó T, Windyga J. Fifth Åland Island conference on von Willebrand disease. Haemophilia. 2018 May; 24 Suppl 4:5-19. View abstract
  27. Staber J, Croteau SE, Davis J, Grabowski EF, Kouides P, Sidonio RF. The spectrum of bleeding in women and girls with haemophilia B. Haemophilia. 2018 Mar; 24(2):180-185. View abstract
  28. Mahajerin A, Croteau SE. Epidemiology and Risk Assessment of Pediatric Venous Thromboembolism. Front Pediatr. 2017; 5:68. View abstract
  29. Croteau SE, Abajas YL, Wolberg AS, Nielsen BI, Marx GR, Baird CW, Neufeld EJ, Monahan PE. Recombinant porcine factor VIII for high-risk surgery in paediatric congenital haemophilia A with high-titre inhibitor. Haemophilia. 2017 Mar; 23(2):e93-e98. View abstract
  30. Hartmann J, Croteau SE. 2017 Clinical trials update: Innovations in hemophilia therapy. Am J Hematol. 2016 12; 91(12):1252-1260. View abstract
  31. Croteau SE, Gupta D. The clinical spectrum of kaposiform hemangioendothelioma and tufted angioma. Semin Cutan Med Surg. 2016 Sep; 35(3):147-52. View abstract
  32. Croteau SE, Nakar C, Neufeld EJ, Shapiro A, Cooper DL. Safety and efficacy of recombinant factor VIIa by pediatric age cohort: reassessment of compassionate use and trial data supporting US label. Pediatr Blood Cancer. 2016 10; 63(10):1822-8. View abstract
  33. Croteau SE, Padula M, Quint K, D'Angelo L, Neufeld EJ. Center-Based Quality Initiative Targets Youth Preparedness for Medical Independence: HEMO-Milestones Tool in a Comprehensive Hemophilia Clinic Setting. Pediatr Blood Cancer. 2016 Mar; 63(3):499-503. View abstract
  34. Croteau SE, Neufeld EJ. Author's response: 'Transition considerations for extended half-life factor products'. Haemophilia. 2015 Sep; 21(5):e454-5. View abstract
  35. Croteau SE, Neufeld EJ. Transition considerations for extended half-life factor products. Haemophilia. 2015 May; 21(3):285-8. View abstract
  36. Archer N, Collins NB, Croteau S, Hong AL, Kamihara J, Kim D, Kort K, Mersereau R, Mosadegh S, Billett A. Use of a fever fast track tool to reduce time to antibiotic dose in febrile pediatric oncology patients. J Clin Oncol. 2014 Oct 20; 32(30_suppl):222. View abstract
  37. Croteau SE, Saxena K, Neufeld EJ. Correlation between dispensed and prescribed doses of factor products for bleeding disorders: can a small, centre-based pharmacy hit the mark? Haemophilia. 2015 Mar; 21(2):190-5. View abstract
  38. Croteau SE, Kozakewich HP, Perez-Atayde AR, Fishman SJ, Alomari AI, Chaudry G, Mulliken JB, Trenor CC. Kaposiform lymphangiomatosis: a distinct aggressive lymphatic anomaly. J Pediatr. 2014 Feb; 164(2):383-8. View abstract
  39. Croteau SE, Luo HY, Lehmann LE, Chui DH, Neufeld EJ. Novel dominant ß-thalassemia: Hb Boston-Kuwait [codon 139/140(+T)]. Pediatr Blood Cancer. 2013 Oct; 60(10):E131-4. View abstract
  40. Croteau SE, Henderson ER, Billett AL, Gebhardt MC, Voss SD. Resolving bony abnormality evolves to diffuse large B-cell lymphoma. Pediatr Blood Cancer. 2013 Oct; 60(10):E113-5. View abstract
  41. Croteau SE, Liang MG, Kozakewich HP, Alomari AI, Fishman SJ, Mulliken JB, Trenor CC. Kaposiform hemangioendothelioma: atypical features and risks of Kasabach-Merritt phenomenon in 107 referrals. J Pediatr. 2013 Jan; 162(1):142-7. View abstract